Mr. Adrian Mendes reports

PERIMETER MEDICAL IMAGING AI APPOINTS FINANCE EXECUTIVE MICHELLE CARON TO BOARD OF DIRECTORS

Perimeter Medical Imaging AI Inc. has appointed Michelle Caron, CPA, to its board of directors, effective immediately.

Adrian Mendes, Perimeter's chief executive officer, stated: "We are thrilled to welcome Michelle to our board. Her extensive finance leadership experience, including her current role as chief financial officer of A10 Networks and her prior tenure across Danaher Corp.'s life sciences businesses, will be a significant asset as we continue to scale our commercial operations and advance our AI-enabled Claire technology. We look forward to benefiting from her strategic counsel."

Ms. Caron commented: "I am excited to join Perimeter's board at such a pivotal time in the company's growth. I look forward to leveraging my financial and operational experience to support Perimeter's continued commercialization efforts and the advancement of its AI-enabled technology."

In a finance career spanning over 28 years, Ms. Caron currently serves as the chief financial officer of A10 Networks, a Nasdaq-listed company delivering secure application and network solutions designed to protect, optimize, and scale business-critical systems across on-premises, hybrid cloud and edge environments. Prior to joining A10 Networks, she was chief financial officer at Beckman Coulter Life Sciences, having previously been group financial officer of Pall and chief financial officer of Phenomenex, all of which are operating companies or subsidiaries under parent organization, Danaher Corp. Prior to joining Danaher, Ms. Caron worked at Philips Healthcare and Stryker Biotech in finance and controller roles. She is a certified public accountant and earned her MBA from Southern Connecticut State University and her BSc in accounting from Central Connecticut State University.

About Perimeter Medical Imaging AI Inc.

Based in Toronto, Canada, and Dallas, Tex., Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire, recently approved by the U.S. Food and Drug Administration (FDA), is the company's next-generation artificial-intelligence-enabled device. The company's ticker symbol, PINK, is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Indications for use: The Claire OCT system is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT system is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

The Claire OCT system should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multicentric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labelling for full safety information.

We seek Safe Harbor.